Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin

Journal of Thrombosis and Thrombolysis

Volumn 8, Issue 3, 1999, Pages 227-232

  Gurfinkel, Enrique ^a,c   Duronto, Ernesto ^a   Coloria, Cecilia ^a   Bozovich, Gerardo ^a   Cohen, Marc ^b   Mautner, Branco ^a  

^a Behavioral and Cognitive Neurology Unit   (Argentina)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Low molecular weight heparin; Thrombotic markers; Unfractionated heparin; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; D DIMER; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBIN TIME; TIME;

BIOLOGICAL MARKERS; CORONARY DISEASE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME;

EID: 0032704982     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008922527826     Document Type: Article

References (24)

1. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis. Circulation 1985;71:912-918.
2. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 fragment and thrombin/antithrombin complex. Blood 1982,59:1086-1097.
3. Theroux P, Latour JG, Leger-Gautier C, De Lara J. Fibrinopeptide A plasma levels and plateled factor 4 levels in unstable angina pectoris. Circulation 1987;75:156-162.
4. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable artery disease. N Engl J Med 1987;317:1361-1365.
5. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
6. Ardissino D, Merlini PA, Gamba G, et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996;93:1634-1639.
7. Theroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, De Guise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
8. Wallentin L, RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
9. Neri-Serneri GG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, Leri A, Margheri M, Casolo GC, Bini M, Rostagno C, Carnovali M, Abbate R. Effect of heparin, aspirin or alteplase in reduction of myocardial ischemia in refractary unstable angina. Lancet 1990;335:615-618.
10. Cohen M, Adams P, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non Q-wave infarction in non-prior aspirin users. Circulation 1994;89: 81-88.
11. Braunwald E, Mark DB, Jones RH et al. Unstable angina: Diagnosis and management. Clinical practice guideline number 10 AHCPR Publication No. 94-0602; Agency for health care policy and research, US Department of Health and Human Services. March 1994.
12. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of acute unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
13. Fragmin during Instability in Coronary Artery Disease (FRISC) Study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347: 561-568.
14. Klein W, Buchwald A, Hillis S, Monrad S, Sanz G, et al for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-68
15. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Langer A, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. Low molecular weight heparin versus unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:449-452.
16. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91:1929-1935.
17. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation of thrombin and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998;79:491-494.
18. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29: 1474-1482.
19. Antman EM, McCabe CH, Premmereur J, Gurfinkel E, Burnink PJLM, Turpie AGG, Bayes de Luna A, LaBlanche JM, Fox KM, Salein D, Radley D, Braunwald E. Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: Results of TIMI 11B. Circulation 1998;98(Suppl I):I-504.
20. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-1228.
21. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993;70:204-207.
22. Becker RC, Corrao JM, Ball SP, Gore JM. A comparison of heparin strategies after thrombolytic therapy. Am Heart J 1993;126:750-752.
23. Toss H, Siegbahn A, Wallentin L. Factor Xa inhibition, efficacy and bleeding tendency are influenced by gender and smoking in low molecular weight heparin treated unstable coronary artery disease. Thromb and Haemost 1997;Suppl-289.
24. Biasucci LM, Liuzzo G, Caliguri G, Quaranta G, Andreotti F, Sperti G, van de Greef W, Rebuzzi A, Kluft C, Maseri A. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996;93:2121-2127.